Furthermore, patients with higher than median tumour expression of HER2 mRNA responded better to ado-trastuzumab emtansine than those with lower than median HER2 mRNA expression (Perez et al, 2014), indicating a relationship between the extent of HER2 expression and responsiveness to treatment. The gene discussed is ERBB2; the disease is neoplasm.